Q-omics provides the consensus-scored MIR7158 profile across patient tissues and cancer cell-line models. MIR7158 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR7158 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR7158 RNA expression shows 9,480 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BRCA, and GBM as cancer lineages where MIR7158 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR7158 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR7158 survival associations across molecular data types. MIR7158 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR7158 RNA expression–survival associations across cancer types. High MIR7158 expression shows unfavorable associations in KIRC, THCA, UVM, PCPG and ESCA, but favorable associations in LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR7158 RNA expression.
This table summarizes MIR7158 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR7158. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR7158 shows lower tumor expression in LUSC, ESCA and LUAD and higher tumor expression in BRCA. The BRCA box plot shows higher MIR7158 RNA expression in tumor versus normal tissue (log2 FC = +0.110, t-test p = .006).
This table shows molecular features associated with MIR7158 in patient tissues and cancer cell lines. In patient samples, MIR7158 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
